Join the club for FREE to access the whole archive and other member benefits.

BioViva tests experimental telomerase gene-therapy in 6 Alzheimer's patients


Key points from article :

BioViva could represent the first recorded attempt to manage dementia that uses an injectable gene therapy technique.

Elizabeth Parrish, CEO of BioVia, was waiting for results from a six-person study that receive a controversial gene therapy injection not yet authorized by the U.S FDA.

The biotech includes an advisory board committee that boasts George Church, a Harvard geneticist.

In 2019, the company said that Integrated Health Systems was initiating a telomerase gene therapy trial for participants with mild to moderate Alzheimer's disease.

No news outlets have been able to confirm the identity or how this therapy affected the patients and their condition.

BioViva has been focused on longevity research for several years.

Parrish received over 100 injections of the investigational gene therapy to switch on telomerase.

Earlier this year, BioViva introduced an at-home genetic home test called the TimeKeeper.

Can estimate the rate of biological aging and how effective an anti-aging intervention may be.

Launched home test to track biological age; outcomes of unlicensed gene-therapy are yet to report

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Company Representative

Founder and CEO of BioViva